Allergic Rhinitis Drugs Market Size & Share 2025 – 2034

Allergic Rhinitis Drugs Market Size

The global allergic rhinitis drugs market size was valued at USD 13.7 billion in 2024 and is estimated to grow at a CAGR of 3.9% from 2025 to 2034. The market for allergic rhinitis drugs is growing due to the increasing prevalence of allergic rhinitis in children and adults.
 

The market is driven by factors such as climate change, pollution, and urbanization. According to the Asthma and Allergy Foundation of America, over 81 million people in America suffered from seasonal allergic rhinitis in 2021. The market is also growing due to increased awareness and better access to healthcare services.
 

The market is witnessing growth due to the introduction of combination therapies, such as antihistamine and corticosteroid sprays, which can manage multiple symptoms at the same time. Other forms of immunotherapy include sublingual (SLIT) and subcutaneous (SCIT) therapies. These treatments provide lasting relief for patients with ongoing allergic rhinitis, which helps expand the market scope. According to the American Academy of Allergy, Asthma & Immunology, these types of immunotherapies can help up to 85% of patients suffering from allergic rhinitis. The development of biologic therapies for patients with severe, hard-to-treat allergic rhinitis is expected to further drive market growth.
 

Allergic rhinitis is an inflammation of the nasal cavities triggered by certain allergens, which is treated using anti-allergic medications known as allergic rhinitis drugs. These medicines help reduce symptoms like sneezing, nasal congestion, itching, and inflammation of the eyes that occur when the body reacts to allergens such as pet hair, dust, or pollen. The most commonly used drugs for allergic rhinitis are antihistamines, intranasal corticosteroids, and immunotherapy.
 

Allergic Rhinitis Drugs Market Trends

Increasing prevalence of allergic rhinitis is a key trend driving the growth of the market.
 

• Allergens like pollen, dust mites, and pet dander are released more often than before due to urbanization, climate change, and environmental degradation. This has led to a higher number of people with allergic rhinitis and has increased the need for treatment.
   
• According to the World Allergy Organization, 10-30% of people worldwide have allergic rhinitis, and this number will continue to increase. Modern lifestyle changes and more exposure to indoor allergens have made the condition more common. This is why more people are seeking treatment.
   
• Prevention and management efforts, along with better health education about available treatments, have strengthened the market. Health awareness campaigns and better access to information have helped patients understand why they need early treatment for their allergic rhinitis.
   
• More people are now using medical care, which has increased the use of medications such as antihistamines, corticosteroids, and immunotherapy. The easy availability of prescription and over-the-counter medicines helps patients take control of their allergic rhinitis, which increases market growth.
   

Allergic Rhinitis Drugs Market Analysis

Based on the disease type, the global market is segmented into perennial allergic rhinitis and seasonal allergic rhinitis. The perennial allergic rhinitis segment dominated the market in 2024, accounting for 58.3% market share.
 

• High market share is due to the widespread prevalence of the condition. Unlike seasonal allergic rhinitis, perennial allergic rhinitis (PAR) is a chronic condition resulting from constant exposure to indoor allergens such as dust mites, pet dander, and mold along with childhood asthma.
   
• Effective medications for PAR such as combination therapies (antihistamines and corticosteroids) and immunotherapy give patients long-term control options. These therapies help reduce symptoms and increase the demand in the PAR segment.
   
• Growing environmental risk factors like indoor pollution and climate change will increase the number of PAR cases, which will increase the demand for PAR treatment and keep this segment at the top.
   

Based on the treatment type, the global allergic rhinitis drugs market is categorized into antihistamines, corticosteroids, immunotherapy, decongestants, combination therapy, and other treatment types. The antihistamines segment was valued at USD 5.5 billion in 2024.
 

• Antihistamines are considered the first choice in managing allergic rhinitis as they help people with a runny nose, itching, and sneezing. The medications are in high demand due to both seasonal and year-round use.
   
• The easy purchase of antihistamines over the counter, along with the availability of oral tablets, nasal sprays, and eye drops, has increased the demand further. Their use as eye and nasal sprays and tablets gives quick relief from symptoms, making them highly preferred among patients. Together with the increasing global spending and easy access to antihistamine products, they are present everywhere across different populations, maintaining a dominant market share.
   

Based on the drug type, the global allergic rhinitis drugs market is divided into prescription and OTC. The prescription segment held significant market share in 2024 and is expected to grow at 3.7% CAGR over the analysis period.
 

• For patients suffering from more complex and persistent symptoms, weekly dose intranasal corticosteroid biologics and add-on therapies are the most beneficial due to their high effectiveness.
   
• Along with better diagnostic techniques, increased public awareness of allergic rhinitis has resulted in more people getting treatment, which has increased the use of prescribed medication.
   
• Many regions provide regulatory support to prescription treatments, ensuring safe usage and giving them a good market position.
   

Based on the route of administration, the global allergic rhinitis drugs market is segmented into oral, nasal, intravenous, and intraocular. The oral segment is anticipated to reach USD 8.4 billion by 2034.
 

• Medications that are taken orally are popular among patients suffering from allergic rhinitis, as they are easy to use and accessible. The ease of use with OTC and prescription options along with the low costs makes them available to a larger group of people.
   
• These drugs are proven to relieve common symptoms like sneezing, itching, and congestion, so they are most commonly used. Moreover, the expansion of the market has also been supported by the introduction of second-generation antihistamines that have little to no side effects.
   

Based on the age group, the global allergic rhinitis drugs market is segmented into children, adults and geriatric. In 2024, the children segment held significant market share of 44.3%.
 

• Children have shown increased allergic rhinitis rates due to high sensitivity to dust mites, pollens, and pet dander. Increased awareness among parents and healthcare providers about timely and effective treatment for children has increased the demand for medications tailored to children. Child-friendly formulations like flavored syrups, chewable tablets, and lower-dose nasal sprays have made it easier to give medications to children.
   
• The focus on innovations in pediatric medicines, along with greater parent concern about medication safety and effectiveness, has positively impacted the demand in this area.
   

Based on the distribution channel, the global allergic rhinitis drugs market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for 43.1% of market share in the global market in 2024.
 

• Pharmaceuticals such as intranasal corticosteroids, combination therapies, and biologics, which are essential for treating moderate to severe allergic rhinitis, are mainly provided by hospital pharmacies.
   
• With a greater focus on chronic and severe conditions, patients seeking specialized care now depend more on hospitals, which increases the need for these medications.
   
• Additionally, the increase in the number of people diagnosed with allergic rhinitis and people visiting hospitals for treatment shows higher awareness and better diagnostic capabilities, which has further strengthened the leading market position of the segment.
   

In 2024, the U.S. dominated North American allergic rhinitis drugs market with a market size  of USD 5.2 billion.
 

• An increase in allergic individuals is attributed to factors like pollution, urbanization, and climate change, as these factors have increased the exposure to allergens. For instance, a report published by the National Health Interview Survey stated that 25.7% of adults over the age of 18 claimed to experience seasonal allergies, while a total of 31.8% suffered from some type of allergy.
   
• Moreover, the growing knowledge and the early detection of allergic rhinitis has also helped in expanding the market.
   
• These factors, as mentioned above, primarily drive the increase in demand for allergic rhinitis drugs in the U.S.
   

Germany is expected to witness considerable growth in the Europe allergic rhinitis drugs market in the coming years.
 

• The presence of pharmaceutical companies in Germany continuously fuels the market as they innovate and create new effective drugs for allergic rhinitis.
   
• Additionally, factors like growing awareness and early diagnosis, well-developed healthcare systems, the high rate of allergic rhinitis, and environmental factors in the country further enhance the growth of the market.
   

The allergic rhinitis drugs market in India is anticipated to experience substantial growth throughout the forecast period.
 

• The rise in allergic conditions is the main reason for market growth. According to the International Journal of Otorhinolaryngology, 20-30% of the Indian population suffers from allergic rhinitis and other allergic disorders. These numbers will increase with the current changes in environment and lifestyle.
   
• Urban expansion exposes people to more airborne allergens and pollution, which increases the risk of allergic diseases.
   
• In India, rapid urbanization and industrialization have changed the quality of the environment, leading to an increase in allergy patients. The major cities of India have seen a decrease in air quality due to pollutants like dust from vehicles, construction activity, and industrial waste.
   

Brazil is projected to witness significant growth in the Latin American allergic rhinitis drugs market during the analysis period.
 

• The country's growing healthcare infrastructure and rising awareness about allergic rhinitis among the population are increasing the demand for effective treatments.
   
• Additionally, the expanding middle-class population with greater access to healthcare services and a preference for advanced therapies contributes to market growth.
   
• Supportive government initiatives and the presence of global pharmaceutical players investing in the Brazilian market further enhance its growth prospects.
   

The allergic rhinitis drugs market in Saudi Arabia is forecasted to experience notable growth in the future.
 

• Increasing cases of allergic rhinitis, driven by exposure to dust, sand, and pollen in the arid environment, are fueling the demand for effective treatments.
   
• Additionally, the growing awareness about the importance of early diagnosis and treatment of allergic rhinitis, along with improving healthcare infrastructure and government initiatives to enhance access to advanced therapies, is supporting market growth.
   

Allergic Rhinitis Drugs Market Share

The market is characterized by intense competition among key players striving to capture a larger market share through strategic initiatives and innovative product offerings. Top 3 players namely, Bayer, GlaxoSmithKline, and Glenmark are contributing more than 40% of the market share. These players compete on various fronts such as pricing strategies, product development, technological advancements, and geographic expansion to maintain their competitive edge.
 

One of the critical bases of competition is product innovation. Companies are investing heavily in research and development to introduce new formulations, such as second-generation antihistamines, nasal sprays, and biologics, offering improved efficacy and reduced side effects. Meanwhile, OTC drug manufacturers are focusing on branding and consumer awareness campaigns to strengthen their market presence. These competitive strategies collectively shape the dynamic landscape of the allergic rhinitis drugs market.
 

To address growing demand and rising awareness, many firms are expanding their geographical footprint, enhancing supply chain efficiency, and leveraging digital platforms for marketing and distribution. Strategic partnerships, acquisitions, and licensing agreements are common practices to strengthen product portfolios and gain a competitive edge. By prioritizing patient needs, such as convenience and affordability, and addressing business challenges like regulatory hurdles and market saturation, companies aim to sustain growth and improve market positioning.
 

Allergic Rhinitis Drugs Market Companies

Few of the prominent players operating in the allergic rhinitis drugs industry include:

• ALK-Abello
• Bayer
• Boehringer Ingelheim
• Dr. Reddy’s Laboratories
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Merck
• Mylan (Viatris)
• Sanofi
• Stallergenes Greer
• Sun Pharmaceuticals
• Teva Pharmaceutical Industries
• Unichem Laboratories
   
• Market leaders such as GlaxoSmithKline offer OTC nasal sprays, with FLONASE and FLONASE Sensimist providing non-drowsy, 24-hour allergy relief. Strong brand recognition and innovative drug formulations significantly influence market growth.
   
• Merck is known for RAGWITEK and GRASTEK. Its sublingual immunotherapy (SLIT) solutions offer long-term allergy relief. Strong research and development in immunotherapy strengthens market growth.
   
• Sanofi's Allegra (fexofenadine) is a well-known non-drowsy antihistamine. Strong OTC and prescription portfolio with advanced anti-allergy solutions drives market growth.
   

Allergic Rhinitis Drugs Industry News

• In August 2022, Hikma Pharmaceuticals and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd., announced the launch of RYALTRIS (olopatadine hydrochloride and mometasone furoate nasal spray) in the U.S. for the treatment of seasonal allergic rhinitis (SAR) symptoms in adult and pediatric patients aged 12 years and older. This launch enhanced Glenmark's market position in the U.S. and expanded its portfolio in the competitive allergic rhinitis market, leading to increased revenue and market share.
   
• In June 2021, Bayer announced that the U.S. Food and Drug Administration (FDA) approved Astepro Allergy (Azelastine HCl 0.15%) as an over-the-counter (OTC) product for the temporary relief of nasal congestion, runny nose, sneezing, and itchy nose caused by hay fever or other upper respiratory allergies. This approval allowed Bayer to tap into the growing OTC allergy treatment market, driving revenue growth.
   
• In May 2021, Glenmark Pharmaceuticals Limited launched the Ryaltris-AZ nasal spray in India for the treatment of moderate to severe allergic rhinitis. This launch has strengthened Glenmark's product portfolio and expanded its presence in the growing allergic rhinitis treatment market.
   

The allergic rhinitis drugs market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Market, By Disease Type

• Perennial allergic rhinitis
• Seasonal allergic rhinitis

Market, By Treatment Type

• Antihistamines
• Corticosteroids
• Immunotherapy
  • Subcutaneous immunotherapy (SCIT)
  • Sublingual immunotherapy (SLIT) 
• Decongestants
• Combination therapy
• Other treatment types

Market, By Drug Type

• Prescription
• OTC

Market, By Route of Administration

• Oral
• Nasal
• Intravenous
• Intraocular

Market, By Age Group

• Children
• Adults
• Geriatric

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE